- Home
- ARQT vs ELVN Comparison
ARQT vs ELVN Comparison
Compare ARQT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ELVN
- Stock Information
- Founded
- ARQT 2016
- ELVN 2016
- Country
- ARQT United States
- ELVN United States
- Employees
- ARQT N/A
- ELVN N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- ELVN Health Care
- Exchange
- ARQT Nasdaq
- ELVN Nasdaq
- Market Cap
- ARQT 1.7B
- ELVN 1.2B
- IPO Year
- ARQT 2020
- ELVN 2020
- Fundamental
- Price
- ARQT $15.76
- ELVN $22.92
- Analyst Decision
- ARQT Strong Buy
- ELVN Strong Buy
- Analyst Count
- ARQT 6
- ELVN 5
- Target Price
- ARQT $18.80
- ELVN $41.20
- AVG Volume (30 Days)
- ARQT 2.0M
- ELVN 728.3K
- Earning Date
- ARQT 08-13-2025
- ELVN 08-12-2025
- Dividend Yield
- ARQT N/A
- ELVN N/A
- EPS Growth
- ARQT N/A
- ELVN N/A
- EPS
- ARQT N/A
- ELVN N/A
- Revenue
- ARQT $212,819,000.00
- ELVN N/A
- Revenue This Year
- ARQT $61.01
- ELVN N/A
- Revenue Next Year
- ARQT $37.95
- ELVN N/A
- P/E Ratio
- ARQT N/A
- ELVN N/A
- Revenue Growth
- ARQT 100.03
- ELVN N/A
- 52 Week Low
- ARQT $7.86
- ELVN $13.30
- 52 Week High
- ARQT $17.75
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- ARQT 60.23
- ELVN 60.45
- Support Level
- ARQT $13.06
- ELVN $19.38
- Resistance Level
- ARQT $15.36
- ELVN $21.34
- Average True Range (ATR)
- ARQT 0.66
- ELVN 1.27
- MACD
- ARQT 0.12
- ELVN 0.11
- Stochastic Oscillator
- ARQT 82.57
- ELVN 88.47
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.